I believe that Nader will be replaced as soon as the company requires operational expertise. Nader has never run any organization (6-8 people doesn't count). Therefore, IMO, the BOD will replace him as soon as it is evident that CYDY plans to go it alone and has the momentum to uplist.
In the meantime, I think the BOD will grin and bear Nader's material short-comings. IMO it is a fact that he: over promises and under delivers, is not effective as a spokesperson, and doesn't understand how to raise institutional money. Those are all material weaknesses for a CEO. His most significant strengths are that he is a bull-dog and knows more about CYDY and the history of leronlimab than any one. If I were chairman of the BOD, I would make Nader a SVP and bring in a seasoned CEO. And if the BOD wanted to wait a little longer, I would make RP the spokesperson of the company and hire a 3rd-party to bring in institutional investors. We have given away far too much dilution because of the lack of any pharma institutional investor support. Retail OTC cannot, and should not, be expected to fuel the launch of a company with this much potential.
Market Data 
Markets 
AI
